ABVX (Abivax) Debt-to-Revenue : N/A (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Abivax Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Abivax's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.57 Mil. Abivax's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $48.92 Mil. Abivax's annualized Revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

Abivax Debt-to-Revenue Historical Data

The historical data trend for Abivax's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Debt-to-Revenue Chart

Abivax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

11,524.00

N/A

Abivax Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Abivax's Debt-to-Revenue

For the Biotechnology subindustry, Abivax's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abivax's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Abivax's Debt-to-Revenue falls into.

Abivax Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Abivax's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(11.567	+	48.917)	/	N/A
	=	N/A

Abivax's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(11.567	+	48.917)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Abivax Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Abivax's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (NAS:ABVX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

0RA9:UK ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.